CSE:NOVO.B 17 January 2026 - 20 March 2026

Novo Nordisk slipped 1.5% to 237.90 Danish crowns in Copenhagen on Thursday, despite the FDA signing off on a higher-dose Wegovy injection. The stock remained in the red after Eli Lilly unveiled new obesity drug results, and as Reuters flagged that semaglutide patent expiry in India could clear the way for lower-cost generics of the compound found in both Wegovy and Ozempic.

Novo Nordisk shares slipped on Monday, giving back a portion of last week’s rally as investors weighed early demand data for the company’s new Wegovy weight-loss drug ahead of the trading week.

Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle.